Your most critical assets deserve more than just fences and cameras. NV5’s cutting-edge layered security solutions extend detection and response beyond traditional perimeters. From advanced geospatial analytics to integrated surveillance and access control, NV5 helps you stay ahead of threats before they breach your defenses. Learn more.
Nuclear manufacturer BWX Technologies has announced its plan to acquire Kinectrics Inc. for approximately $525 million. The deal is expected to close in mid-2025.
An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich SE (ITM) announced they have begun commercial production of lutetium-177 using Unit 7 of the Bruce nuclear power plant in Kincardine, Ontario. According to the companies, this marks the first time a commercial power reactor has been used to commercially produce short-lived medical radioisotopes.
An international collaboration between Bruce Power, Isogen (a joint venture of Kinectrics and Framatome), and ITM Isotope Technologies Munich SE, announced a milestone marking the first time that lutetium-177, a short-lived medical radioisotope, has been produced in a commercial nuclear power reactor.
The Canadian Nuclear Safety Commission and the U.S. Nuclear Regulatory Commission have completed the first collaborative project under a two-year-old memorandum of cooperation (MOC) aimed at enhancing technical reviews of advanced reactor and small modular reactor technologies, the CNSC announced earlier this week.
The project, a 23-page joint report from the regulators on a white paper submitted last July by X-energy regarding reactor pressure vessel (RPV) construction code specifications for the company’s Xe-100 SMR, was released to the public on August 6. The Xe-100 is an 80-MWe unit that can be scaled into a “four-pack” 320-MWe power plant, according to X-energy.